Munim Khan
Internal Medicine · Boston, MANPI 1730670423
Payments from drug & device makers
What this record shows
This record is dominated by grants: $20,333 of the $32,428 with a category attached, or 62.7%. 25 manufacturers reported payments, led by Abbott at 50.2% of the total. 2025 is the largest year on record at $18,206, more than ten times the $598 reported in 2021. Among internal medicine clinicians in MA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 193 payments — averaging $168.02 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Abbott$16K
- Medtronic$9K
- Boston Scientific$4K
- Johnson & Johnson$387
- AstraZeneca$345
- Amgen$324
- plus $2K from 19 others
What the payments were for
- Grants$20,33363%
- Travel & lodging$3,67311%
- Food & beverage$8,09425%
- Education$3271%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Abbott | 59 | $16,267 |
| Medtronic | 8 | $8,726 |
| Boston Scientific | 16 | $3,945 |
| Johnson & Johnson | 7 | $387 |
| AstraZeneca | 10 | $345 |
| Amgen | 14 | $324 |
| Pfizer | 12 | $316 |
| Abiomed | 6 | $277 |
| Alnylam Pharmaceuticals Inc. | 11 | $274 |
| Biotronik Inc. | 2 | $261 |
| Daiichi Sankyo Inc. | 10 | $241 |
| Biosense Webster, Inc. | 4 | $238 |
| Novartis | 12 | $205 |
| Chiesi USA, Inc. | 1 | $150 |
| Boehringer Ingelheim | 4 | $94 |
| Kiniksa Pharmaceuticals, Ltd. | 4 | $90 |
| Novo Nordisk | 3 | $60 |
| Regeneron Healthcare Solutions, Inc. | 2 | $51 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 2 | $48 |
| E.r. Squibb & Sons, L.L.C. | 1 | $30 |
| Kiniksa Pharmaceuticals International, PLC | 1 | $25 |
| Cordis US CORP. | 1 | $25 |
| Merck | 1 | $18 |
| Acacia Pharma Inc | 1 | $17 |
| Esperion Therapeutics, Inc. | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- TACTICATH$3,000
- ASSURITY$3,000
- GENERAL EP$2,112
- ENSITE$1,847
- Farapulse$299
- AVEIR$250
- ENSITE PRECISION$247
- HeartMate Touch$150
- KENGREAL$150
- WATCHMAN FLX$133
- JOT DX$128
- FARXIGA$125
- ONPATTRO$125
- QDOT MICRO Catheter$124
- XARELTO$117
How this compares
$32,428 in reported general payments places this provider in the 95th percentile of 4,983 internal medicine providers in Massachusetts.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EntrestoSacubitril/Valsartan | 48 | $67,265 |
| EliquisApixaban | 38 | $51,922 |
| JardianceEmpagliflozin | 30 | $38,282 |
| FarxigaDapagliflozin Propanediol | 35 | $34,008 |
| Repatha SureclickEvolocumab | 36 | $25,390 |
| Rosuvastatin Calcium | 17 | $1,191 |
| Metoprolol Succinate | 66 | $1,166 |
| Atorvastatin Calcium | 36 | $791 |
| Ezetimibe | 13 | $395 |
| Valsartan | 19 | $373 |
| Torsemide | 15 | $241 |
| Lisinopril | 32 | $241 |
| Furosemide | 23 | $225 |
| Losartan Potassium | 20 | $200 |
| Spironolactone | 18 | $184 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| NovartisEntresto | $205 | $67,26548 claims |
| PfizerEliquis | $316 | $51,92238 claims |
| Boehringer IngelheimJardiance | $94 | $38,28230 claims |
| AstraZenecaFarxiga | $345 | $34,00835 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 4,983 internal medicine providers in Massachusetts.
Other internal medicine in Boston
- David SchenkeinBoston$5M
- John FallonBoston$1.8M
- Michael MendelsohnBoston$1.6M
- Gaurav SingalBoston$798K
- Asit ParikhBoston$486K
- Noopur RajeBoston$481K
- Daniel KuritzkesBoston$443K
- Xiuning leBoston$364K
- Nancy GaglianoBoston$358K
- Fatima StanfordBoston$285K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.